ArriVent BioPharma, Inc. (AVBP)
Develops cancer drugs targeting specific genetic mutations in lung and gastrointestinal tumors.
$29.98-0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+60.7%
The outlook
AVBP is trading near $30 with unanimous analyst support at "Strong Buy," and the average price target sits roughly 49% above the current level. The stock sits in the upper portion of its 52-week range but shows mixed signals relative to short-term moving averages. Overall sentiment leans constructive based on analyst coverage.
What’s behind the score
Analyst consensusStrong Buy — 1.0 avg of 10 analysts
Price trendMixed vs its moving averages
52-week range70% of the way from its 52-week low to high
Price targetAvg target +49% vs current price
Analyst price target
~12-month · 10 analysts$44.60average target+48.8% vs now
Now $29.98
Low $42.00High $50.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
—
52-wk high
$35.83
52-wk low
$16.10
50-day avg
$31.05
200-day avg
$25.14
Trailing P/E
—